Stevanato Group S.p.A. (STVN)

Market Cap	8.45B
Revenue (ttm)	1.21B
Net Income (ttm)	161.81M
Shares Out	303.80M
EPS (ttm)	0.59
PE Ratio	47.42
Forward PE	44.02
Dividend	$0.06 (0.21%)
Ex-Dividend Date	Jun 7, 2023

Volume	41,425
Open	27.98
Previous Close	27.52
Day's Range	27.81 - 28.17
52-Week Range	23.00 - 36.30
Beta	0.70
Analysts	Buy
Price Target	34.38 (+23.47%)
Earnings Date	May 9, 2024

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines,...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 5,634
• Stock Exchange: NYSE
• Ticker Symbol: STVN

Financial Performance

In 2023, STVN's revenue was 1.09 billion, an increase of 10.34% compared to the previous year's 983.68 million. Earnings were 145.63 million, an increase of 1.95%.

Financial numbers in EUR

Analyst Forecast

According to 8 analysts, the average rating for STVN stock is "Buy." The 12-month stock price forecast is $34.38, which is an increase of 23.47% from the latest price.

Price Target

$34.38

(23.47% upside)

Analyst Consensus: Buy